Targeted treatments in advanced renal cell carcinoma: focus on axitinib

Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Verzoni, Elena, Grassi, Paolo, Testa, Isabella, Iacovelli, Roberto, Biondani, Pamela, Garanzini, Enrico, De Braud, Filippo, Procopio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977458/
https://www.ncbi.nlm.nih.gov/pubmed/24715765
http://dx.doi.org/10.2147/PGPM.S37098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977458/
https://www.ncbi.nlm.nih.gov/pubmed/24715765
http://dx.doi.org/10.2147/PGPM.S37098

Ejemplares similares